News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Endotis Pharma Reports Successful Completion of Phase I Program with EP42675, a First in Class Synthetic Parenteral Anticoagulant


5/19/2009 10:49:53 AM

PARIS--(BUSINESS WIRE)--BIOCITECH PARK, Paris- Endotis Pharma, the biopharmaceutical company dedicated to the discovery and development of small-glyco drugs for applications in thrombosis and oncology, announced that EP42675 has successfully completed its Phase I program.

Read at BioSpace.com

Related News

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES